• Welcome, Guest. Please login or register.
    October 19, 2019, 03:36:03 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55138 Posts in 5876 Topics by 6155 Members
Latest Member: S1m0n3

Forum Tip: 
Put your birthdate in your profile, under "Forum Profile Information," and it will automatically come up on our calendar.
« previous next »
Pages: 1 Go Down Print
Author Topic: Another clinical trial coming in 2018 for Beta Thalassemia  (Read 2038 times)
Bostonian_04
Senior Member
****
Offline Offline

Location: Boston

Gender: Male
Posts: 392


« on: December 19, 2017, 07:39:32 PM »

CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia
-Phase 1/2 trial in β-thalassemia expected to begin in 2018.

http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2321577

Andy, what are your thoughts on this trial?
Logged

Quis custodiet ipsos custodes ? - Plato
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8599


Will thal rule you or will you rule thal?


« Reply #1 on: December 21, 2017, 06:31:50 PM »

Until more is known about the long term effects of editing genes, so they are passed onto progeny, I think they need to go very slow with gene editing. I feel that more needs to be known about the interactions among genes before this technique can be fully trusted.
Logged

Andy

All we are saying is give thals a chance.
catchR
Active Member
**
Offline Offline

Posts: 88


« Reply #2 on: April 25, 2018, 12:43:26 PM »

Europe's first clinical trial to use genome editing in humans has received approval to start later this year.

CRISPR Therapeutics, headquartered in Zug, Switzerland, has got the regulatory go-ahead to test its therapy in patients with the inherited blood disorder, beta-thalassemia. So far, China has been the only country, which has used genome editing techniques to treat patients in clinical trials (see BioNews 935).

The biotechnology company applied for regulatory approval to test CTX001 in patients with beta-thalassemia and sickle cell disease in December last year.

'Beta-thalassemia is a devastating disease that requires serious and chronic medical intervention,' said Dr Tony Ho, head of research and development at CRISPR Therapeutics, at the time of that announcement. 'The efficient and precise editing in a patient's own blood cells using CRISPR provides the possibility of a one-time treatment for those suffering from beta-thalassemia and sickle cell disease.'

The therapy, developed by CRISPR Therapeutics in collaboration with Vertex Pharmaceuticals, works by extracting a patient's blood stem cells and then using genome editing to make them produce high levels of fetal haemoglobin in red blood cells. The cells are then transfused back into the same patient. By elevating the levels of this type of haemoglobin in a patient's blood, researchers hope to alleviate the need for blood transfusions in beta-thalassemia patients and avoid sickle cell crises in sickle cell patients.

The approved trial aims to test the safety and efficacy of the therapy in adult beta-thalassemia patients in Europe.

'Certainly, 2018 promises to be the big year for clinical trials using CRISPR based genome editing,' geneticist Dr Helen O'Neill, at University College London, told the Telegraph. 'Results presented by [CRISPR Therapeutics] at a haematology meeting showed that the method dramatically increased fetal hemoglobin in beta thalassemia patients' cells. The therapy successfully edited over 90 percent of blood stem cells removed from patients, which were re-transfused.'

Professor Robin Lovell-Badge, at the Francis Crick Institute in London, said: 'Assuming they do get going, we will look back and think that this is the real beginning of gene therapy.'


Link: https://www.bionews.org.uk/page_135374
Logged
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!